{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:12:26Z","timestamp":1784128346100,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273406"],"award-info":[{"award-number":["82273406"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304221"],"award-info":[{"award-number":["82304221"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473049"],"award-info":[{"award-number":["82473049"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1245\/s10434-025-17809-5","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T16:14:45Z","timestamp":1752509685000},"page":"7173-7182","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Genomic and Clinical Predictors of Conversion in Initially Unresectable Colorectal Cancer Liver Metastases"],"prefix":"10.1245","volume":"32","author":[{"given":"Daocheng","family":"Zuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangpeng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueming","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"17809_CR1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02736","author":"A Kawazoe","year":"2024","unstructured":"Kawazoe A, et al. Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer: final analysis of the randomized, ppen-label, phase III LEAP-017 study. J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/JCO.23.02736.","journal-title":"J Clin Oncol"},{"key":"17809_CR2","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ccell.2021.03.004","volume":"39","author":"A Bertocchi","year":"2021","unstructured":"Bertocchi A, et al. Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver. Cancer Cell. 2021;39:708\u201324. https:\/\/doi.org\/10.1016\/j.ccell.2021.03.004.","journal-title":"Cancer Cell"},{"key":"17809_CR3","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1158\/2159-8290.CD-21-0316","volume":"12","author":"Y Wu","year":"2022","unstructured":"Wu Y, et al. Spatiotemporal immune landscape of colorectal cancer liver metastasis at single-cell level. Cancer Discov. 2022;12:134\u201353. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0316.","journal-title":"Cancer Discov"},{"key":"17809_CR4","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1097\/SLA.0000000000002552","volume":"267","author":"GA Margonis","year":"2018","unstructured":"Margonis GA, et al. Impact of surgical margin width on recurrence and overall survival following R0 hepatic resection of colorectal metastases: a systematic review and meta-analysis. Ann Surg. 2018;267:1047\u201355. https:\/\/doi.org\/10.1097\/SLA.0000000000002552.","journal-title":"Ann Surg"},{"key":"17809_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216967","volume":"593","author":"Q Chen","year":"2024","unstructured":"Chen Q, et al. Personalized prediction of postoperative complication and survival among colorectal liver metastases patients receiving simultaneous resection using machine learning approaches: a multi-center study. Cancer Lett. 2024;593:216967. https:\/\/doi.org\/10.1016\/j.canlet.2024.216967.","journal-title":"Cancer Lett"},{"key":"17809_CR6","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S2468-1253(24)00091-8","volume":"9","author":"D Wankhede","year":"2024","unstructured":"Wankhede D, et al. Clinical significance of combined tumour-infiltrating lymphocytes and microsatellite instability status in colorectal cancer: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2024;9:609\u201319. https:\/\/doi.org\/10.1016\/S2468-1253(24)00091-8.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"17809_CR7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/00000658-199909000-00004","volume":"230","author":"Y Fong","year":"1999","unstructured":"Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309\u201318. https:\/\/doi.org\/10.1097\/00000658-199909000-00004.","journal-title":"Ann Surg"},{"key":"17809_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/SLA.0b013e31815aa2c2","volume":"247","author":"M Rees","year":"2008","unstructured":"Rees M, Tekkis PP, Welsh FK, O\u2019Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008;247:125\u201335. https:\/\/doi.org\/10.1097\/SLA.0b013e31815aa2c2.","journal-title":"Ann Surg"},{"key":"17809_CR9","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1200\/JCO.22.01690","volume":"41","author":"VK Morris","year":"2023","unstructured":"Morris VK, et al. Treatment of metastatic colorectal cancer: ASCO guideline. J Clin Oncol. 2023;41:678\u2013700. https:\/\/doi.org\/10.1200\/JCO.22.01690.","journal-title":"J Clin Oncol"},{"key":"17809_CR10","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jamasurg.2015.0313","volume":"150","author":"GA Margonis","year":"2015","unstructured":"Margonis GA, et al. Association between specific mutations in KRAS codon 12 and colorectal liver metastasis. JAMA Surg. 2015;150:722\u20139. https:\/\/doi.org\/10.1001\/jamasurg.2015.0313.","journal-title":"JAMA Surg"},{"key":"17809_CR11","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1200\/JCO.2008.20.5278","volume":"27","author":"S Kopetz","year":"2009","unstructured":"Kopetz S, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27:3677\u201383. https:\/\/doi.org\/10.1200\/JCO.2008.20.5278.","journal-title":"J Clin Oncol"},{"key":"17809_CR12","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","volume":"371","author":"F Loupakis","year":"2014","unstructured":"Loupakis F, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014;371:1609\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1403108.","journal-title":"N Engl J Med"},{"key":"17809_CR13","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1093\/annonc\/mdz134","volume":"30","author":"AB Schrock","year":"2019","unstructured":"Schrock AB, et al. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol. 2019;30:1096\u2013103. https:\/\/doi.org\/10.1093\/annonc\/mdz134.","journal-title":"Ann Oncol"},{"key":"17809_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.6004\/jnccn.2013.0023","volume":"11","author":"FM Johnston","year":"2013","unstructured":"Johnston FM, Mavros MN, Herman JM, Pawlik TM. Local therapies for hepatic metastases. J Natl Compr Cancer Netw. 2013;11:153\u201360. https:\/\/doi.org\/10.6004\/jnccn.2013.0023.","journal-title":"J Natl Compr Cancer Netw"},{"key":"17809_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.semcancer.2020.09.008","volume":"71","author":"E Schadde","year":"2021","unstructured":"Schadde E, Grunhagen DJ, Verhoef C, Krzywon L, Metrakos P. Limitations in resectability of colorectal liver metastases 2020: a systematic approach for clinicians and patients. Semin Cancer Biol. 2021;71:10\u201320. https:\/\/doi.org\/10.1016\/j.semcancer.2020.09.008.","journal-title":"Semin Cancer Biol"},{"key":"17809_CR16","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/S1470-2045(19)30798-3","volume":"21","author":"JA Bridgewater","year":"2020","unstructured":"Bridgewater JA, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (new EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21:398\u2013411. https:\/\/doi.org\/10.1016\/S1470-2045(19)30798-3.","journal-title":"Lancet Oncol"},{"key":"17809_CR17","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.annonc.2023.02.016","volume":"34","author":"J Ros","year":"2023","unstructured":"Ros J, et al. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments. Ann Oncol. 2023;34:543\u201352. https:\/\/doi.org\/10.1016\/j.annonc.2023.02.016.","journal-title":"Ann Oncol"},{"key":"17809_CR18","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1093\/annonc\/mdy061","volume":"29","author":"JB Bachet","year":"2018","unstructured":"Bachet JB, et al. RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study. Ann Oncol. 2018;29:1211\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdy061.","journal-title":"Ann Oncol"},{"key":"17809_CR19","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1200\/JCO.2008.17.8301","volume":"26","author":"G Nasti","year":"2008","unstructured":"Nasti G, Ottaiano A, Rosario Iaffaioli V, Berretta M, Delrio P. Trials on preoperative chemotherapy in resectable colorectal liver metastases need prospective evaluation of predictive factors of response. J Clin Oncol. 2008;26:3812\u20133. https:\/\/doi.org\/10.1200\/JCO.2008.17.8301.","journal-title":"J Clin Oncol"},{"key":"17809_CR20","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/SLA.0b013e31822b8cfa","volume":"254","author":"J Garcia-Aguilar","year":"2011","unstructured":"Garcia-Aguilar J, et al. Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer. Ann Surg. 2011;254:486\u201392. https:\/\/doi.org\/10.1097\/SLA.0b013e31822b8cfa.","journal-title":"Ann Surg"},{"key":"17809_CR21","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2018.0996","volume":"153","author":"GA Margonis","year":"2018","unstructured":"Margonis GA, et al. Association of BRAF mutations with survival and recurrence in surgically treated patients with metastatic colorectal liver cancer. JAMA Surg. 2018;153:e180996. https:\/\/doi.org\/10.1001\/jamasurg.2018.0996.","journal-title":"JAMA Surg"},{"key":"17809_CR22","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/ng.2538","volume":"45","author":"LG Morris","year":"2013","unstructured":"Morris LG, et al. Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nat Genet. 2013;45:253\u201361. https:\/\/doi.org\/10.1038\/ng.2538.","journal-title":"Nat Genet"},{"key":"17809_CR23","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12876-023-02896-z","volume":"23","author":"L Zhou","year":"2023","unstructured":"Zhou L, et al. Comprehensive analysis of CXCL14 uncovers its role during liver metastasis in colon cancer. BMC Gastroenterol. 2023;23:273. https:\/\/doi.org\/10.1186\/s12876-023-02896-z.","journal-title":"BMC Gastroenterol"},{"key":"17809_CR24","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/ng.2727","volume":"45","author":"GL Carvill","year":"2013","unstructured":"Carvill GL, et al. GRIN2A mutations cause epilepsy-aphasia spectrum disorders. Nat Genet. 2013;45:1073\u20136. https:\/\/doi.org\/10.1038\/ng.2727.","journal-title":"Nat Genet"},{"key":"17809_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156665","volume":"11","author":"A Palaniappan","year":"2016","unstructured":"Palaniappan A, Ramar K, Ramalingam S. Computational identification of novel stage-specific biomarkers in colorectal cancer progression. PLoS ONE. 2016;11:e0156665. https:\/\/doi.org\/10.1371\/journal.pone.0156665.","journal-title":"PLoS ONE"},{"key":"17809_CR26","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1038\/s41591-021-01553-w","volume":"27","author":"Y Nakamura","year":"2021","unstructured":"Nakamura Y, et al. Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. Nat Med. 2021;27:1899\u2013903. https:\/\/doi.org\/10.1038\/s41591-021-01553-w.","journal-title":"Nat Med"},{"key":"17809_CR27","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(21)00086-3","volume":"22","author":"S Siena","year":"2021","unstructured":"Siena S, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2021;22:779\u201389. https:\/\/doi.org\/10.1016\/S1470-2045(21)00086-3.","journal-title":"Lancet Oncol"},{"key":"17809_CR28","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.jtho.2019.10.015","volume":"15","author":"J Noe","year":"2020","unstructured":"Noe J, et al. ALK mutation status before and after alectinib treatment in locally advanced or metastatic ALK-positive NSCLC: pooled analysis of two prospective trials. J Thorac Oncol. 2020;15:601\u20138. https:\/\/doi.org\/10.1016\/j.jtho.2019.10.015.","journal-title":"J Thorac Oncol"},{"key":"17809_CR29","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1093\/annonc\/mdx095","volume":"28","author":"G Siravegna","year":"2017","unstructured":"Siravegna G, et al. Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor. Ann Oncol. 2017;28:1302\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdx095.","journal-title":"Ann Oncol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17809-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17809-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17809-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T14:05:45Z","timestamp":1758549945000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17809-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["17809"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17809-5","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"assertion":[{"value":"15 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}